bioAffinity Technologies, Inc.

Snapshot

bioAffinity is a tiny diagnostics company selling its CyPath Lung cancer test, with FY2025 revenue of $6.2M, down 34% from a smaller prior-year base, and a net loss of $14.9M.

What's Happening Right Now

• Fri 28th Aug '26 · Delisting risk: Nasdaq notified BIAF on July 30, 2026 that it's out of compliance with the $1.00 minimum bid price rule, and because of a prior reverse split the company doesn't get the usual 180-day grace period; it's appealing to a Nasdaq panel.
• Thu 27th Aug '26 · Registration: Registered 1.71M shares for sale on Form S-3.
• Thu 20th Aug '26 · Reverse split: BIAF executed a 1-for-15 reverse stock split effective August 24, 2026, primarily to try to regain Nasdaq compliance, leaving about 592,373 shares outstanding post-split.
• Fri 14th Aug '26 · Offering: Raised $3.94M in gross proceeds through a private placement (PIPE), with warrants over 1.71M shares.
• Fri 7th Aug '26 · Earnings: Q2 2026 revenue rose 19% YoY to $1.5M on a 216% jump in CyPath Lung test volume, and the net loss narrowed to $3.4M from $4.1M, though cash stood at just $2.4M after a $3.2M offering.
• Thu 30th Jul '26 · Partnership: On July 30, 2026, BIAF announced a collaboration with Pictor, Inc. to co-develop diagnostic tests for asthma and COPD, aiming to launch them as lab-developed tests.
• Tue 30th Jun '26 · ATM sale: Sold $1.20M of stock / 8K shares through its at-the-market program.
• Fri 12th Jun '26 · Going concern: In a June 12, 2026 S-1 filing to raise ~$3.4M, BIAF disclosed only $3.1M in cash and a $72.2M accumulated deficit, and its auditor issued a going-concern warning tied to the company's ability to keep operating without more capital.